Skip to main content

Author: Customer Service

ISC Reports Financial Results for the Three Months and Year Ended December 31, 2025

Record annual revenue and adjusted EBITDA of $257.8 million and $103.1 million; annual EPS (diluted) $1.43 Strong high–value registration activity in the Saskatchewan Land Registry, supported by favourable macroeconomic conditions Achieved long-term net leverage target range of 2.0x–2.5x, ahead of scheduleCapitalized terms that are used but not defined in this news release, including section references, have the meanings ascribed to those terms in Management’s Discussion and Analysis for the three months and year ended December 31, 2025. REGINA, Saskatchewan, March 19, 2026 (GLOBE NEWSWIRE) — Information Services Corporation (TSX:ISC) (ISC or the Company) today reported on the Company’s financial results for the quarter and year ended December 31, 2025. Commenting on ISC’s results, Shawn Peters, President and CEO...

Continue reading

Grupo Aeroportuario del Pacifico Announces Refinancing of Bank Loan for USD$95.5 Million

GUADALAJARA, Mexico, March 19, 2026 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (the “Company” or “GAP”) announced that today it refinanced a bank loan for USD$95.5 million with BBVA México, S.A., which was due on this same date, by entering into a new financing agreement with the same institution. The new loan has a six-month term, with the option to extend for an additional six months, with interest payable monthly at a variable rate equivalent to SOFR plus 40 basis points. It also includes a structuring fee of 10 basis points and, if the extension option is exercised, an additional fee of 10 basis points. The principal will be paid at maturity. Company Description Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including...

Continue reading

Maxim Power Corp. Announces 2025 Fourth Quarter Financial and Operating Results

CALGARY, Alberta, March 19, 2026 (GLOBE NEWSWIRE) — Maxim Power Corp. (“MAXIM” or the “Corporation”) (TSX: MXG) announced today the release of financial and operating results for the fourth quarter ended December 31, 2025. The audited consolidated financial statements, accompanying notes and Management’s Discussion and Analysis (“MD&A”) will be available on SEDAR+ and on MAXIM’s website on March 19, 2026. All figures reported herein are Canadian dollars unless otherwise stated. FINANCIAL HIGHLIGHTS  Three Months EndedDecember 31, Twelve Months EndedDecember 31,($ in thousands except per share amounts) 2025   2024   2025   2024  Revenue 17,966   24,048   86,873   101,482  Net income (loss) 2,422   (341 ) 16,694   21,946  Earnings (loss) per share – basic 0.04   (0.01 ) 0.26   0.42  Earnings...

Continue reading

BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10207584/1039b7a7360. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730....

Continue reading

Condor Announces 2025 Year-End Results

CALGARY, Alberta, March 19, 2026 (GLOBE NEWSWIRE) — Condor Energies Inc. (“Condor” or the “Company”) (TSX:CDR), a Canadian based, internationally focused energy transition company focused on Central Asia is pleased to announce the release of its audited consolidated financial statements for the years ended December 31, 2025 and 2024 (the Financial Statements”), together with the related management’s discussion and analysis. These documents will be made available under Condor’s profile on SEDAR+ at www.sedarplus.ca and on the Condor website at www.condorenergies.ca. Readers are invited to review the latest corporate presentation available on the Condor website. All financial amounts in this news release are presented in Canadian dollars, unless otherwise stated. HIGHLIGHTSProduction in Uzbekistan for the fourth quarter of 2025...

Continue reading

CORRECTION – Hammond Power Solutions Reports Fourth Quarter 2025 Financial Results

(Dollar amounts are in thousands, in Canadian currency unless otherwise specified) GUELPH, Ontario, March 19, 2026 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Hammond Power Solutions Inc. (TSX: HPS.A), please note that the Quarterly adjusted EBITDA should be 15.2% of sales, not 13.5% as previously stated. The corrected release follows: Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX: HPS.A) a leading manufacturer of dry-type transformers, power quality products and related magnetics, today announced its financial results for the fourth quarter 2025. QUARTERLY HIGHLIGHTS:Record annual sales of $898 million, a 13.9% increase versus 2024; Quarterly adjusted EBITDA of $38.7 million, or 15.2% of sales; Record annual adjusted EBITDA of $133.3 million, or 14.8% of sales; Quarterly adjusted...

Continue reading

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoingPhase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoingBest-in-class dual allogeneic CAR-T cell product targeting CD20 & CD22 At current dose level, 88% ORR; 63% CR rate after 2+ prior lines of therapy 93% of subjects had prior CD19 CAR-T Low-dose IL-2 cohort to be included in; Full Phase 1 dataset expected in Q4 2026PartnershipsServier (through Allogene): Pivotal randomized Phase 2 ALPHA3 trial with cema-cel in 1L consolidation in LBCL: interim futility analysis evaluating MRD clearance and early safety...

Continue reading

Diversified Royalty Corp. Announces Fourth Quarter and Year End 2025 Results

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) — Diversified Royalty Corp. (TSX: DIV, DIV.DB.A and DIV.DB.B) (the “Corporation” or “DIV”) is pleased to announce its financial results for the three months (“Q4 2025”) and year ended December 31, 2025. HighlightsThe weighted average organic royalty growth1 of DIV’s diversified royalty portfolio was 3.0% in Q4 2025 and 4.1% for the year ended December 31, 2025, compared to 5.2% for the three months ended December 31, 2024 (“Q4 2024”) and 4.6% for the year ended December 31, 2024. The weighted average organic royalty growth1 on a constant currency basis was 3.0% in Q4 2025 and 3.8% for the year ended December 31, 2025, compared to 4.8% for Q4 2024 and 4.3% for the year ended December 31, 2024. Revenue was $19.1 million in Q4 2025 and $70.8 million for the year ended...

Continue reading

Pacific Health Care Organization, Inc. Reports its 2025 Year-End Financial Results

Irvine, CA, March 19, 2026 (GLOBE NEWSWIRE) — Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed Tuesday with the Securities and Exchange Commission (the “SEC”) its annual report on Form 10-K announcing its financial results for the fiscal year ended December 31, 2025. Results The Company reported total revenues of $6,715,175 for the year ended December 31, 2025 (“fiscal year 2025”), compared to $6,065,390 for the year ended December 31, 2024 (“fiscal year 2024”). The Company reported income from operations of $1,001,038 for fiscal year 2025, compared to income from operations of $852,623 for fiscal year 2024. The Company realized net income of $1,387,647 or $0.11 per weighted average share outstanding, basic and diluted, for fiscal year 2025, compared to net income of $883,584 or $0.07 per weighted...

Continue reading

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

David Meeker QuoteDavid Meeker QuoteDr. Shoemaker quoteDr. Shoemaker quoteIMCIVREE packagingIMCIVREE packaging with vialIMCIVREE 3D RenderIMCIVREE 3D Render— First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction –  — Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity — — Approval based on -18.4% placebo-adjusted BMI reduction achieved by setmelanotide in global Phase 3 TRANSCEND trial [N=142] — — Company to host conference call today at 7:00 p.m. ET — BOSTON, March 19, 2026 (GLOBE NEWSWIRE) — Rhythm...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.